Literature DB >> 14616791

Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG.

M Mahmoodi1, A Khamesipour, Y Dowlati, S Rafati, A Z Momeni, M Emamjomeh, H Hejazi, F Modabber.   

Abstract

The immune responses induced against Leishmania antigens in volunteers who were vaccinated in a double-blind, randomized field efficacy trial of a preparation of autoclaved Leishmania major (ALM) mixed with a low dose of Bacille Calmette-Guerin vaccine (BCG) who developed either a cutaneous leishmaniasis (CL) lesion due to exposure to infected sandfly bite(s) or did not develop a lesion during the course of the trial were studied and compared with those of non-vaccinated controls. Blood samples were also assayed from different groups including volunteers with history of CL and volunteers with previous positive or negative leishmanin skin test (LST) without a history of CL. The vaccinated volunteers had received a single dose of either ALM mixed with a low dose of BCG or the same dose of BCG alone. The LST and in vitro proliferative response (stimulation index, SI), interferon gamma (IFN-gamma) production and, in a few cases, interleukin (IL)-4 production of peripheral blood mononuclear cells to soluble Leishmania antigens were measured. The results indicated that volunteers who developed CL in the vaccine arm showed a slightly higher SI than cases who received BCG alone. Volunteers with history of CL and volunteers with positive LST demonstrated the strongest proliferation indices and IFN-gamma production. The data suggest that a single dose of ALM + BCG induces a weak Th1 response in vaccinated volunteers that is far lower than that in volunteers with prior subclinical infection or volunteers with history of CL, who are presumed to be immune.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14616791      PMCID: PMC1808866          DOI: 10.1046/j.1365-2249.2003.02299.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  15 in total

1.  A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran.

Authors:  A Z Momeni; T Jalayer; M Emamjomeh; A Khamesipour; F Zicker; R L Ghassemi; Y Dowlati; I Sharifi; M Aminjavaheri; A Shafiei; M H Alimohammadian; R Hashemi-Fesharki; K Nasseri; T Godal; P G Smith; F Modabber
Journal:  Vaccine       Date:  1999-02-05       Impact factor: 3.641

2.  Immunotherapy of localized, intermediate, and diffuse forms of American cutaneous leishmaniasis.

Authors:  J Convit; P L Castellanos; M Ulrich; M Castés; A Rondón; M E Pinardi; N Rodríquez; B R Bloom; S Formica; L Valecillos
Journal:  J Infect Dis       Date:  1989-07       Impact factor: 5.226

Review 3.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

4.  Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses.

Authors:  E Nascimento; W Mayrink; C A da Costa; M S Michalick; M N Melo; G C Barros; M Dias; C M Antunes; M S Lima; D C Taboada
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

5.  A sensitive immunochemical assay for biologically active MuIFN-gamma.

Authors:  R C Curry; P A Kiener; G L Spitalny
Journal:  J Immunol Methods       Date:  1987-11-23       Impact factor: 2.303

6.  The effect of BCG on experimental cutaneous leishmaniasis in mice.

Authors:  J Weintraub; F I Weinbaum
Journal:  J Immunol       Date:  1977-06       Impact factor: 5.422

7.  Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine.

Authors:  H W Murray; B Y Rubin; C D Rothermel
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

8.  Visceral leishmaniasis: a disease associated with inability of lymphocytes to activate macrophages to kill leishmania.

Authors:  E M Carvalho; O A Bacellar; S Reed; A Barral; H Rocha
Journal:  Braz J Med Biol Res       Date:  1988       Impact factor: 2.590

9.  Leishmania major infection in BALB/c mice: protection or exacerbation by treatment with different doses of BCG.

Authors:  M M Stefani; I Müller; J Louis
Journal:  Res Immunol       Date:  1993-05

10.  Frozen stored Leishmania tropica vaccine: the effects of dose, route of administration and storage on the evolution of the clinical lesion. Two field trials in the Israel Defense Forces.

Authors:  M S Green; J D Kark; E Witztum; C L Greenblatt; D T Spira
Journal:  Trans R Soc Trop Med Hyg       Date:  1983       Impact factor: 2.184

View more
  17 in total

1.  Low prevalence of Leishmania infection in post-epidemic areas of Libo Kemkem, Ethiopia.

Authors:  Luis Sordo; Endalamaw Gadisa; Estefanía Custodio; Israel Cruz; Fernando Simón; Zelalem Abraham; Javier Moreno; Abraham Aseffa; Hailu Tsegaye; Javier Nieto; Carmen Chicharro; Carmen Cañavate
Journal:  Am J Trop Med Hyg       Date:  2012-06       Impact factor: 2.345

2.  Serological and Molecular Analysis of Leishmania Infection in Healthy Individuals from Two Districts of West Bengal, India, Endemic for Visceral Leishmaniasis.

Authors:  Himanshu Kaushal; Sujit Kumar Bhattacharya; Sandeep Verma; Poonam Salotra
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

Review 3.  Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies.

Authors:  Ifeoma Okwor; Jude Uzonna
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

4.  CCR7+ central and CCR7- effector memory CD4+ T cells in human cutaneous leishmaniasis.

Authors:  Hossein Keshavarz Valian; Mahmoud Nateghi Rostami; Minoo Tasbihi; Akram Miramin Mohammadi; Seyed Ebrahim Eskandari; Abdolfattah Sarrafnejad; Ali Khamesipour
Journal:  J Clin Immunol       Date:  2012-09-19       Impact factor: 8.317

5.  Usefulness of the rK39-immunochromatographic test, direct agglutination test, and leishmanin skin test for detecting asymptomatic Leishmania infection in children in a new visceral leishmaniasis focus in Amhara State, Ethiopia.

Authors:  Endalamaw Gadisa; Estefanía Custodio; Carmen Cañavate; Luis Sordo; Zelalem Abebe; Javier Nieto; Carmen Chicharro; Abraham Aseffa; Lawrence Yamuah; Howard Engers; Javier Moreno; Israel Cruz
Journal:  Am J Trop Med Hyg       Date:  2012-05       Impact factor: 2.345

6.  CD8+ T cells as a source of IFN-γ production in human cutaneous leishmaniasis.

Authors:  Mahmoud Nateghi Rostami; Hossein Keshavarz; Rosita Edalat; Abdolfattah Sarrafnejad; Tahereh Shahrestani; Fereidoun Mahboudi; Ali Khamesipour
Journal:  PLoS Negl Trop Dis       Date:  2010-10-12

7.  Anti-leishmanial effects of trinitroglycerin in BALB/C mice infected with Leishmania major via nitric oxide pathway.

Authors:  Hossein Nahrevanian; Mana Najafzadeh; Reza Hajihosseini; Habib Nazem; Mahin Farahmand; Zahra Zamani
Journal:  Korean J Parasitol       Date:  2009-05-27       Impact factor: 1.341

8.  CD26 expression on CD4+T cells in patients with cutaneous leishmaniasis.

Authors:  R Jafari-Shakib; S Ajdary; Z Mohtasham Amiri; A M Mohammadi; K Nourijelyani; H Mortazavi; M A Shokrgozar; B Nikbin; A Khamesipour
Journal:  Clin Exp Immunol       Date:  2008-05-05       Impact factor: 4.330

9.  Role of Mycobacterium vaccae in the protection induced by first generation Leishmania vaccine against murine model of leishmaniasis.

Authors:  Hosein Keshavarz Valian; Lavinia Khoshabe Abdollah Kenedy; Mahmoud Nateghi Rostami; Akram Miramin Mohammadi; Ali Khamesipour
Journal:  Parasitol Res       Date:  2008-06       Impact factor: 2.289

Review 10.  Potential biomarkers of immune protection in human leishmaniasis.

Authors:  Mahmoud Nateghi Rostami; Ali Khamesipour
Journal:  Med Microbiol Immunol       Date:  2021-05-02       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.